Close Menu

10X Genomics

 

10x Genomics, Inc. is an American company incorporated in 2012 that develops and manufactures integrated systems for whole genome sequencing, exome sequencing and single cell transcriptomics. Its headquarters are located in Pleasanton, California.

 

10X Genomics Company Profile  

 

President & CEO: Serge Saxonov

CEO photo:

 10X Genomics CEO photo - Serge Saxonov

Website: http://10xgenomics.com

Headquarters: Pleasanton, CA

10x Genomics employees: 101-250

Funding: $113M USD

Founded: 2012

Founders: Serge Saxonov, Ben Hindson


 

10x Genomics News 

Bio-Rad claims that 10x Genomics infringes on patents it holds related to emulsion formation in microfluidics chips. 

The researchers plan to profile patients with both Adaptive Biotechnologies' ImmunoSeq platform and 10x Genomics' single-cell immune repertoire profiling technology. 

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.

The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.

Specialized single-cell "cores" are popping up to help scientists get the most out of new technologies.

The single-cell VDJ profiling kit is the first of a suite of immunology products the company plans to launch this year.

Following an inter partes review requested by 10x Genomics, the Patent Trial and Appeal Board invalidated a number of claims in a RainDance patent.

The two new single-cell RNA-sequencing methods aim to overcome some of the limitations of single-cell transcriptomics.

Executives provided updates on their companies at the 35th Annual JP Morgan Healthcare Conference in San Francisco, CA, Day Two

The companies will merge 10x's Chromium system and PerkinElmer's automation solutions into a combined NGS solution for researchers.

Pages

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.